Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

3.65

Margin Of Safety %

-16

Put/Call OI Ratio

0.13

EPS Next Q Diff

-0.02

EPS Last/This Y

2.03

EPS This/Next Y

-0.12

Price

40.56

Target Price

44.5

Analyst Recom

1.67

Performance Q

16.88

Relative Volume

3.39

Beta

1.7

Ticker: VCYT




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19VCYT39.060.280.924962
2024-12-20VCYT40.90.280.144985
2024-12-23VCYT41.010.080.372517
2024-12-24VCYT41.180.090.882540
2024-12-26VCYT40.950.090.002552
2024-12-27VCYT40.150.092.072573
2024-12-30VCYT40.010.100.642615
2024-12-31VCYT39.580.111.082648
2025-01-02VCYT40.210.120.032685
2025-01-03VCYT41.880.110.552716
2025-01-06VCYT43.390.130.292792
2025-01-07VCYT42.470.140.502840
2025-01-08VCYT43.80.142.172843
2025-01-09VCYT43.780.142.172843
2025-01-10VCYT41.530.131.672851
2025-01-13VCYT42.760.130.652871
2025-01-14VCYT41.140.131.362874
2025-01-15VCYT41.690.130.672883
2025-01-16VCYT40.850.130.302880
2025-01-17VCYT40.570.130.172904
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19VCYT39.07165.9100.21.01
2024-12-20VCYT40.90165.9106.11.01
2024-12-23VCYT40.99165.9101.61.01
2024-12-24VCYT41.18165.9101.81.01
2024-12-26VCYT40.95165.9100.81.01
2024-12-27VCYT40.13165.999.31.01
2024-12-30VCYT39.98165.9101.01.01
2024-12-31VCYT39.60165.9100.31.01
2025-01-02VCYT40.39165.9103.41.01
2025-01-03VCYT41.85165.9104.91.01
2025-01-06VCYT43.36165.9104.91.01
2025-01-07VCYT42.47165.999.21.01
2025-01-08VCYT43.78165.9104.41.01
2025-01-09VCYT43.78165.9101.31.01
2025-01-10VCYT41.54165.996.21.01
2025-01-13VCYT42.76165.9104.31.01
2025-01-14VCYT41.10165.997.41.01
2025-01-15VCYT41.72165.9103.01.01
2025-01-16VCYT41.08165.999.81.01
2025-01-17VCYT40.56165.9100.01.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19VCYT-13.403.023.88
2024-12-20VCYT-13.403.023.88
2024-12-23VCYT-12.883.023.88
2024-12-24VCYT-12.963.023.88
2024-12-26VCYT-13.423.023.33
2024-12-27VCYT-13.483.023.33
2024-12-30VCYT-13.722.913.33
2024-12-31VCYT-13.722.913.33
2025-01-02VCYT-13.602.913.33
2025-01-03VCYT-15.672.913.33
2025-01-06VCYT-15.212.923.33
2025-01-07VCYT-15.952.923.33
2025-01-08VCYT-16.442.923.33
2025-01-09VCYT-16.442.923.33
2025-01-10VCYT-16.442.923.33
2025-01-13VCYT-16.443.003.65
2025-01-14VCYT-16.103.003.65
2025-01-15VCYT-16.103.003.65
2025-01-16VCYT-16.103.003.65
2025-01-17VCYT-16.103.003.65
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.19

Avg. EPS Est. Current Quarter

0.26

Avg. EPS Est. Next Quarter

0.17

Insider Transactions

-16.1

Institutional Transactions

3

Beta

1.7

Average Sales Estimate Current Quarter

116

Average Sales Estimate Next Quarter

110

Fair Value

33.97

Quality Score

59

Growth Score

56

Sentiment Score

20

Actual DrawDown %

52.9

Max Drawdown 5-Year %

-81.2

Target Price

44.5

P/E

Forward P/E

63.68

PEG

P/S

7.39

P/B

2.67

P/Free Cash Flow

55.68

EPS

-0.14

Average EPS Est. Cur. Y​

1.01

EPS Next Y. (Est.)

0.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2.18

Relative Volume

3.39

Return on Equity vs Sector %

-19.9

Return on Equity vs Industry %

-11.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.25

EBIT Estimation

100
Veracyte, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 815
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
stock quote shares VCYT – Veracyte, Inc. Stock Price stock today
news today VCYT – Veracyte, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VCYT – Veracyte, Inc. yahoo finance google finance
stock history VCYT – Veracyte, Inc. invest stock market
stock prices VCYT premarket after hours
ticker VCYT fair value insiders trading